Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Eli Lilly and Company
Telix Pharmaceuticals (Innovations) Pty Limited
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Hoffmann-La Roche
Neonc Technologies, Inc.